Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up

from Biotech Blueprint · host Katerina Roznik

This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com. KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema data (Jan 16-22, 2026).

Episode metadata supplied by the publisher feed · Published Jan 23, 2026

Embed this episode

Attribution link and audio player

Ready to play

Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up

0:00 7:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Research in Action Oracle Corporation "Research in Action" explores the dynamic world of life sciences, covering drug discovery, clinical trials, therapeutic development, and the pivotal role of real-world data and technology in connecting clinical research with patient care. Hear insightful conversations with scientists, clinicians, and leaders from pharma, biotech, and health.

Frequently Asked Questions

How long is this episode of Biotech Blueprint?

This episode is 7 minutes long.

When was this Biotech Blueprint episode published?

This episode was published on January 23, 2026.

Can I download this Biotech Blueprint episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!